
$STSS is now in the commercial stage, shifting from R&D to generating real revenue. In mid-2025, we completed our first product shipments to customers in the U.S. and Europe, officially marking the start of sales for our SoloGard, SecureGard, and low-dead-space syringes. #Nasdaq
English
